Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab + serplulimab is a combination therapy consisting of the HER2-targeted monoclonal antibody trastuzumab and the PD-1-targeted monoclonal antibody serplulimab. This combination is being investigated, often alongside chemotherapy, for the treatment of HER2-overexpressing advanced malignancies, specifically biliary tract cancer and urothelial carcinoma. Trastuzumab works by binding to the HER2 receptor on tumor cells, inhibiting proliferation and promoting antibody-dependent cellular cytotoxicity (ADCC). Serplulimab (HLX10) is a humanized IgG4 monoclonal antibody that blocks the PD-1/PD-L1 pathway, thereby reactivating the immune system's anti-tumor response. The combination is currently being evaluated in the Phase II SHIELD trial (NCT05501444) led by investigator Xiujuan Qu for patients who have failed standard therapies.
- Brand names
- HANSOHUA
- Other names
- HLX10HLX-10HLX 10anti-PD-1 monoclonal antibody HLX10anti-PD1 monoclonal antibody HLX10anti-PD 1 monoclonal antibody HLX10
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + serplulimab.